SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-23-234349 from Ambrx Biopharma, Inc. (CIK 0001990550)

Ambrx Biopharma, Inc. (CIK 0001990550)
Date: Sept. 13, 2023 · CIK: 0001990550 · Accession: 0001193125-23-234349

AI Filing Summary & Sentiment

File numbers found in text: 333-274230

Date
September 13, 2023
Author
/s/ Daniel J. O’Connor
Form
CORRESP
Company
Ambrx Biopharma, Inc. (CIK 0001990550)

Letter

New Ambrx Biopharma Inc.

10975 North Torrey Pines Road

La Jolla, CA 92037

September 13, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller

Re:

New Ambrx Biopharma Inc.

Registration Statement on Form S-4

File No. 333-274230

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, New Ambrx Biopharma Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced Registration Statement to 4:00 p.m., Eastern Time, on September 15, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Skadden, Arps, Slate, Meagher & Flom LLP, request by telephone that such Registration Statement be declared effective.

Please contact Raymond Bogenrief, of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at (312) 407-0550, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.

Sincerely,
/s/ Daniel J. O’Connor

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 New Ambrx Biopharma Inc.

10975 North Torrey Pines Road

La Jolla, CA 92037

September 13, 2023

 VIA EDGAR

 Securities and Exchange Commission

 Division of
Corporation Finance

 Office of Life Sciences

 100 F Street,
N.E.

 Washington, D.C. 20549

 Attention: Tim Buchmiller

Re:

 New Ambrx Biopharma Inc.

 Registration
Statement on Form S-4

 File No. 333-274230

 Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, New Ambrx Biopharma Inc. (the “Company”) hereby requests
acceleration of the effective date of the above referenced Registration Statement to 4:00 p.m., Eastern Time, on September 15, 2023, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Skadden,
Arps, Slate, Meagher & Flom LLP, request by telephone that such Registration Statement be declared effective.

 Please contact
Raymond Bogenrief, of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at (312) 407-0550, as soon as the Registration Statement has been declared effective, or if you have any
other questions or concerns regarding this matter.

Sincerely,

/s/ Daniel J. O’Connor

Daniel J. O’Connor

President and Chief Executive Officer